Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 36
- +1 vs. Q2 2024
- Portfolio value
- $1.60B
- +$135.3M (+9.2%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| MRUSMerus N.V. | COM | 3,350,000 | $167.4M | 10.5% | +150,000+4.7% | Added | History |
| VERAVera Therapeutics, Inc. | CL A | 2,475,000 | $109.4M | 6.8% | 00.0% | Unchanged | History |
| XENEXenon Pharmaceuticals Inc. | COM | 2,700,000 | $106.3M | 6.6% | −54,266−2.0% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 920,000 | $105.1M | 6.6% | −385,000−29.5% | Reduced | History |
| ELVNEnliven Therapeutics, Inc. | COM | 4,100,000 | $104.7M | 6.5% | +126,755+3.2% | Added | History |
| NUVLNuvalent, Inc. | COM | 940,000 | $96.2M | 6.0% | −547,756−36.8% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 7,539,930 | $81.4M | 5.1% | −2,198,070−22.6% | Reduced | History |
| ALKSAlkermes plc. | SHS | 2,900,000 | $81.2M | 5.1% | +1,525,000+110.9% | Added | History |
| SLNOSoleno Therapeutics Inc | COM | 1,260,000 | $63.6M | 4.0% | −165,000−11.6% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,988,084 | $58.5M | 3.7% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,550,124 | $58.0M | 3.6% | +22,092+0.9% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 1,618,937 | $55.0M | 3.4% | +193,937+13.6% | Added | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 8,000,000 | $45.5M | 2.8% | +854,112+12.0% | Added | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 3,350,000 | $44.7M | 2.8% | −1,307,345−28.1% | Reduced | History |
| NRIXNurix Therapeutics, Inc. | COM | 1,650,000 | $37.1M | 2.3% | +1,650,000 | New | History |
| PHVSPharvaris N.V. | COM | 1,911,433 | $35.4M | 2.2% | +101,258+5.6% | Added | History |
| KURAKura Oncology, Inc. | COM | 1,800,000 | $35.2M | 2.2% | +206,650+13.0% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 650,000 | $34.1M | 2.1% | −575,000−46.9% | Reduced | History |
| ORKAOruka Therapeutics, Inc. | COM | 1,369,714 | $33.6M | 2.1% | +1,369,714 | New | History |
| ARVNArvinas, Inc. | COM | 1,200,000 | $29.6M | 1.8% | −684,361−36.3% | Reduced | History |
| CELCCelcuity Inc. | COM | 1,522,332 | $22.7M | 1.4% | +58,227+4.0% | Added | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,350,000 | $21.6M | 1.3% | +1,350,000 | New | History |
| NKTXNkarta, Inc. | COM | 4,662,073 | $21.1M | 1.3% | +511,039+12.3% | Added | History |
| ORICOric Pharmaceuticals, Inc. | COM | 2,000,000 | $20.5M | 1.3% | 00.0% | Unchanged | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 3,410,384 | $19.4M | 1.2% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 1,360,569 | $18.4M | 1.2% | −184,857−12.0% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 885,000 | $17.0M | 1.1% | +60,000+7.3% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 290,000 | $17.0M | 1.1% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,284,110 | $14.8M | 0.9% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM NEW | 150,929 | $10.2M | 0.6% | +150,929 | New | History |
| NGNENeurogene Inc. | COM | 200,000 | $8.39M | 0.5% | 00.0% | Unchanged | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 750,000 | $7.51M | 0.5% | 00.0% | Unchanged | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.22M | 0.3% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 1,100,000 | $5.19M | 0.3% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,575,000 | $4.74M | 0.3% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 483,000 | $4.59M | 0.3% | +443,000+1,107.5% | Added | History |
Sold out since Q2 2024 (3)
Positions held at the end of Q2 2024 that are gone from this filing.